MAP17 contributes to non-small cell lung cancer progression via suppressing miR-27a-3p expression and p38 signaling pathway

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Yu N, Yong S, Kim HK, Choi YL, Jung Y, Kim D, Seo J, Lee YE, Baek D, Lee J, et al. 2019. Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor-normal samples in lung adenocarcinoma. Mol Oncol. 13:1356–1368. doi:10.1002/1878-0261.12478.
   PubMed Web of Science ®Google Scholar
• Ferrer I, Quintanal-Villalonga A, Molina-Pinelo S, Garcia-Heredia JM, Perez M, Suarez R, Ponce-Aix S, Paz-Ares L, Carnero A. 2018. MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. J Exp Clin Cancer Res. 37:195. doi:10.1186/s13046-018-0871-7.
   PubMed Web of Science ®Google Scholar
• Chen S, Wang Q, Zhou XM, Zhu JP, Li T, Huang M. 2016. MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth factor receptor. Mol Med Rep. 14:949–954. doi:10.3892/mmr.2016.5332.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. doi:10.3322/caac.21332.
   PubMed Web of Science ®Google Scholar
• Guijarro MV, Link W, Rosado A, Leal JF, Carnero A. 2007. MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation. Carcinogenesis. 28:2443–2450. doi:10.1093/carcin/bgm154.
   PubMed Web of Science ®Google Scholar
• Jaeger C, Schaefer BM, Wallich R, Kramer MD. 2000. The membrane-associated protein pKe#192/MAP17 in human keratinocytes. J Invest Dermatol. 115:375–380. doi:10.1046/j.1523-1747.2000.00071.x.
   PubMed Web of Science ®Google Scholar
• Kocher O, Cheresh P, Brown LF, Lee SW. Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique. Clin Cancer Res. 1995;1:1209–1215.
   PubMed Web of Science ®Google Scholar
• Garcia-Heredia JM, Jekyll CA, Hyde M. 2018. MAP17’s up-regulation, a crosspoint in cancer and inflammatory diseases. Mol Cancer. 17:80. doi:10.1186/s12943-018-0828-7.
   PubMed Web of Science ®Google Scholar
• de Miguel-luken MJ, Chaves-Conde M, de Miguel-luken V, Munoz-Galvan S, Lopez-Guerra JL, Mateos JC, Pachon J, Chinchon D, Suarez V, Carnero A. 2015. MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer. Oncotarget. 6:12625–12636. doi:10.18632/oncotarget.3470.
   PubMedGoogle Scholar
• Guijarro MV, Leal JF, Blanco-Aparicio C, Alonso S, Fominaya J, Lleonart M, Castellvi J, Ramon Y Cajal S, Carnero A. 2007. MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis. 28:2096–2104. doi:10.1093/carcin/bgm124.
   PubMed Web of Science ®Google Scholar
• Shao Y, Lv H, Zhong DS, Zhou QH. 2018. EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties. Oncol Lett. 15:6655–6665. doi:10.3892/ol.2018.8129.
   PubMed Web of Science ®Google Scholar
• Perez M, Peinado-Serrano J, Garcia-Heredia JM, Felipe-Abrio I, Tous C, Ferrer I, Martin-Broto J, Saez C, Carnero A. 2016. Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). Oncotarget. 7:67033–67046. doi:10.18632/oncotarget.11475.
   PubMedGoogle Scholar
• Guijarro MV, Vergel M, Marin JJ, Munoz-Galvan S, Ferrer I, Ramon Y Cajal S, Roncador G, Blanco-Aparicio C, Carnero A. 2012. p38alpha limits the contribution of MAP17 to cancer progression in breast tumors. Oncogene. 31:4447–4459. doi:10.1038/onc.2011.619.
   PubMed Web of Science ®Google Scholar
• Ambros V. 2004. The functions of animal microRNAs. Nature. 431:350–355. doi:10.1038/nature02871.
   PubMed Web of Science ®Google Scholar
• Moghaddam T, Neshati Z. 2019. Role of microRNAs in osteogenesis of stem cells. J Cell Biochem. 120:14136–14155. doi:10.1002/jcb.28689.
   PubMed Web of Science ®Google Scholar
• Li L, Li Y, Tang C. 2019. The role of microRNAs in the involvement of vascular smooth muscle cells in the development of atherosclerosis. Cell Biol Int. 43:1102–1112. doi:10.1002/cbin.11164.
   PubMed Web of Science ®Google Scholar
• Wu F, Yang Z, Li G. 2009. Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun. 386:549–553. doi:10.1016/j.bbrc.2009.06.075.
   PubMed Web of Science ®Google Scholar
• Skaftnesmo KO, Prestegarden L, Micklem DR, Lorens JB. MicroRNAs in tumorigenesis. Curr Pharm Biotechnol. 2007;8:320–325. doi:10.2174/138920107783018390.
   PubMed Web of Science ®Google Scholar
• Liu ZM, Wu ZY, Li WH, Wang LQ, Wan JN, Zhong Y. 2019. MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67. Eur Rev Med Pharmacol Sci. 23:3421–3430. doi:10.26355/eurrev_201904_17706.
   PubMed Web of Science ®Google Scholar
• Bai TL, Liu YB, Li BH. 2019. MiR-411 inhibits gastric cancer proliferation and migration through targeting SETD6. Eur Rev Med Pharmacol Sci. 23:3344–3350. doi:10.26355/eurrev_201904_17697.
   PubMed Web of Science ®Google Scholar
• Xu Q, Cheng L, Chen J, Lu W, Wang P. 2019. miR-376a inhibits the proliferation and invasion of osteosarcoma by targeting FBXO11. Hum Cell. 32:390–396. doi:10.1007/s13577-019-00256-2.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhu Y, Hu L, Yan F, Chen J. 2019. miR-494 induces EndMT and promotes the development of HCC (Hepatocellular carcinoma) by targeting SIRT3/TGF-beta/SMAD signaling pathway. Sci Rep. 9:7213. doi:10.1038/s41598-019-43731-4.
   PubMed Web of Science ®Google Scholar
• He S, Wang Z, Tang H, Dong J, Qu Y, Lv J. 2019. MiR-217 inhibits proliferation, migration, and invasion by targeting SIRT1 in osteosarcoma. Cancer Biother Radiopharm. 34:264–270. doi:10.1089/cbr.2017.2394.
   PubMed Web of Science ®Google Scholar
• Peng H, Wang X, Zhang P, Sun T, Ren X, Xia Z. miR-27a promotes cell proliferation and metastasis in renal cell carcinoma. Int J Clin Exp Pathol. 2015;8:2259–2266.
   PubMed Web of Science ®Google Scholar
• Guttilla IK, White BA. 2009. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 284:23204–23216. doi:10.1074/jbc.M109.031427.
   PubMed Web of Science ®Google Scholar
• Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, Yao X, Pan Z, Zhang P, Li J, et al. 2008. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer. 123:972–978. doi:10.1002/ijc.23580.
   PubMed Web of Science ®Google Scholar
• Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. 2007. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 67:11001–11011. doi:10.1158/0008-5472.CAN-07-2416.
   PubMed Web of Science ®Google Scholar
• Su C, Huang DP, Liu JW, Liu WY, Cao YO. 2019. miR-27a-3p regulates proliferation and apoptosis of colon cancer cells by potentially targeting BTG1. Oncol Lett. 18:2825–2834. doi:10.3892/ol.2019.10629.
   PubMed Web of Science ®Google Scholar
• Zhou L, Liang X, Zhang L, Yang L, Nagao N, Wu H, Liu C, Lin S, Cai G, Liu J. 2016. MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget. 7:51943–51954. doi:10.18632/oncotarget.10460.
   PubMedGoogle Scholar
• Yang Y, Zang A, Jia Y, Shang Y, Zhang Z, Ge K, Zhang J, Fan W, Wang B. 2016. Genistein inhibits A549 human lung cancer cell proliferation via miR-27a and MET signaling. Oncol Lett. 12:2189–2193. doi:10.3892/ol.2016.4817.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. doi:10.1006/meth.2001.1262.
   PubMed Web of Science ®Google Scholar
• Yoon D, Bae K, Kim JH, Choi YK, Yoon KA. Oncogenic effect of the novel fusion gene VAPA-Rab31 in lung adenocarcinoma. Int J Mol Sci. 2019;20. doi:10.3390/ijms20092309.
   Web of Science ®Google Scholar
• Tian H, Zhang Y, Zhang Q, Li S, Liu Y, Han X. 2019. Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells. Biosci Trends. 13:40–48. doi:10.5582/bst.2019.01006.
   PubMed Web of Science ®Google Scholar
• Luo J, Yao Y, Ji S, Sun Q, Xu Y, Liu K, Diao Q, Qiang Y, Shen Y. 2019. PITX2 enhances progression of lung adenocarcinoma by transcriptionally regulating WNT3A and activating Wnt/beta-catenin signaling pathway. Cancer Cell Int. 19:96. doi:10.1186/s12935-019-0800-7.
   PubMed Web of Science ®Google Scholar
• Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, et al. 2019. LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma. Cancer Res. 79:3251–3267. doi:10.1158/0008-5472.CAN-18-3527.
   PubMed Web of Science ®Google Scholar
• Luo J, Liu Z. 2019. Long non-coding RNA TTN-AS1 promotes the progression of lung adenocarcinoma by regulating PTEN/PI3K/AKT signaling pathway. Biochem Biophys Res Commun. 514:140–147. doi:10.1016/j.bbrc.2019.04.050.
   PubMed Web of Science ®Google Scholar
• Chen X, Liao Y, Yu Y, Zhu P, Li J, Qin L, Liao W, Huang Z. 2017. Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma. Oncotarget. 8:92589–92603. doi:10.18632/oncotarget.21506.
   PubMedGoogle Scholar
• Perez M, Praena-Fernandez JM, Felipe-Abrio B, Lopez-Garcia MA, Lucena-Cacace A, Garcia A, Lleonart M, Roncador G, Marin JJ, Carnero A. 2013. MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. PLoS One. 8:e56169. doi:10.1371/journal.pone.0056169.
   PubMed Web of Science ®Google Scholar
• Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, Castellvi J, Ruiz L, Ramon YCS, Carnero A. 2007. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis. 28:1646–1652. doi:10.1093/carcin/bgm083.
   PubMed Web of Science ®Google Scholar
• Marzi L, Combes E, Vie N, Ayrolles-Torro A, Tosi D, Desigaud D, Perez-Gracia E, Larbouret C, Montagut C, Iglesias M, et al. 2016. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. Br J Cancer. 115:1223–1233. doi:10.1038/bjc.2016.313.
   PubMed Web of Science ®Google Scholar
• Hong B, Li H, Zhang M, Xu J, Lu Y, Zheng Y, Qian J, Chang JT, Yang J, Yi Q. 2015. p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer. 136:34–43. doi:10.1002/ijc.28958.
   PubMed Web of Science ®Google Scholar
• Bulavin DV, Fornace AJ Jr. 2004. p38 MAP kinase’s emerging role as a tumor suppressor. Adv Cancer Res. 92:95–118. doi:10.1016/S0065-230X(04)92005-2.
   PubMed Web of Science ®Google Scholar
• Xia ZX, Li ZX, Zhang M, Sun LM, Zhang QF, Qiu XS. 2016. CARMA3 regulates the invasion, migration, and apoptosis of non-small cell lung cancer cells by activating NF-small ka, CyrillicB and suppressing the P38 MAPK signaling pathway. Exp Mol Pathol. 100:353–360. doi:10.1016/j.yexmp.2015.10.004.
   PubMed Web of Science ®Google Scholar
• Xu Q, Tong JL, Zhang CP, Xiao Q, Lin XL, Xiao XY. 2017. miR-27a induced by colon cancer cells in HLECs promotes lymphangiogenesis by targeting SMAD4. PLoS One. 12:e0186718. doi:10.1371/journal.pone.0186718.
   PubMed Web of Science ®Google Scholar
• Ow SH, Chua PJ, Bay BH. 2018. miR-149 as a potential molecular target for cancer. Curr Med Chem. 25:1046–1054. doi:10.2174/0929867324666170718102738.
   PubMed Web of Science ®Google Scholar
• Zhang HD, Jiang LH, Sun DW, Li J, Ji ZL. 2017. The role of miR-130a in cancer. Breast Cancer. 24:521–527. doi:10.1007/s12282-017-0776-x.
   PubMed Web of Science ®Google Scholar
• Danza K, Silvestris N, Simone G, Signorile M, Saragoni L, Brunetti O, Monti M, Mazzotta A, De Summa S, Mangia A, et al. 2016. Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. Cancer Biol Ther. 17:400–406. doi:10.1080/15384047.2016.1139244.
   PubMed Web of Science ®Google Scholar
• Li J, Wang Y, Song Y, Fu Z, Yu W. 2014. miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol Cancer. 13:193. doi:10.1186/1476-4598-13-193.
   PubMed Web of Science ®Google Scholar